Helping you make wiser investment decisions

Fierce Pharma Asia—Eisai's reduced Aduhelm role; Chinese biotechs' US delisting risks; Zai Lab's new COO from Lilly

March 18, 2022 aliu



Fierce Pharma Asia—Eisai’s reduced Aduhelm role; Chinese biotechs’ US delisting risks; Zai Lab’s new COO from Lilly
aliu
Fri, 03/18/2022 – 06:28



Source link